Board summary
Key figures
52,201
Registered population
62.4% aged 18–64
8.8%
Aged 65+
ICB 14.9% · England 17.9%
61.9%
Ethnic minority (non-White)
47.5% Asian · England 9.6%
87.7%
In IMD quintile 1
ICB 40.7% · England 21.0%
~33,968
Core20 residents (est.)
Resident basis; registered basis ~47,505 · see page 3
5,531
Hypertension register
+3.89% in 3 yrs · England +5.60%
592
SMI register
16.3% of Bolton (LAD)'s
662
COPD register
Reviews +5.14% in 3 yrs
Forecast to 2030
6,205
Hypertension patients, 2030
+674 on today
73.8%
QRISK ≥20% on statins, 2030
+0.56pp over 3 yrs
1.6%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Breast and cervical screening trail England.
Breast screening is 57.3% (England 69.9%) and cervical screening ages 25-49 is 56.5% (England 66.8%), which may reflect unverified recall or access barriers.
Pre-school booster lags the 95.0% target.
Age-5 4-in-1 coverage is 81.5% (13.5 pp below the 95.0% target) and MMR2 is 87.6% despite 97.0% MMR1, which may indicate follow-up gaps.
Chronic disease register reviews exceed England.
Heart failure reviews reach 89.8% (England 78.5%), COPD reviews 87.3% (England 76.4%) and QRISK ≥ 20% lipid therapy 72.7% (England 63.6%).
Population, age and ethnicity
Bolton Central PCN has a young profile and a 47.5% Asian resident share
Bolton Central PCN serves 52,201 registered patients. Children aged 0–17 comprise 28.8% of the list (15,047 patients), above Bolton (LAD) (23.7%), NHS Greater Manchester Integrated Care Board (21.8%) and England (19.6%). Patients aged 65+ account for 8.8% (4,592 patients), below Bolton (LAD) (14.7%), the ICB (14.9%) and England (17.9%). Census usual residents in associated areas are 47.5% Asian / Asian British (England 9.6%) and 38.1% White (England 81.1%). The younger age structure may influence crude chronic disease registers, which local age-stratified reviews can test.
Age profile
65+: ICB 14.9%, England 17.9%
Ethnicity
Older people · falls rows are Bolton (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Bolton LA) | 1,923 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 79.2% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 51.6% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Bolton LA) | 958 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Bolton LA) | 19.0 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 patients comprise 87.7% of the PCN, with average IMD decile 2.0
The PCN has 87.7% of registered patients in the Core20 cohort, compared with 47.8% in Bolton (LAD), 40.7% in NHS Greater Manchester Integrated Care Board and 21.0% in England, with an average IMD decile of 2.0 (England 5.5). Practice concentration spans 31.5 pp, from Bradford Street Surgery at 68.5% to Deane Medical Centre at 100.0%. Practice-level registered Core20 estimates sum to 47,505 patients, whereas resident deciles 1 and 2 total 33,968. Resource allocation requires reconciling registered patient estimates with resident counts to target high-volume practices.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
592
SMI register
1.11% recorded prevalence
331
Learning disability register
0.62% recorded prevalence
22
Care homes, 702 beds
In the PCN catchment
9.8%
Provide unpaid care
Bolton (LAD), Census 2021
Recorded severe mental illness includes 592 patients (1.1%, above England's 1.0%), while learning disability prevalence is 0.6% (331 patients, matching England). The catchment includes 22 care homes with 702 beds. Borough-level carers (9.8%) and rough sleeping (5) cannot be directly extrapolated. The SMI register slightly exceeds England, so maintaining proactive physical health checks and coordinating care home reviews represent the primary vulnerable-group workload to prioritise.
Severe mental illness: physical health checks
SMI blood pressure checks reached 86.0% (England 83.4%) and BMI recording reached 86.6% (England 82.1%). Three-year BMI recording rose +0.8 pp, trailing England's +5.1 pp rise. Slower progress may indicate momentum loss across physical health checks.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
5,531
Hypertension register
+3.89%
Register growth, 3 yrs
Bolton (LAD) +4.70% · England +5.60%
−2.39pp
BP control, under 80
≤140/90 · +0.71pp aged 80+
+674
More patients by 2030
Forecast 6,205 (11.17%)
Hypertension case-finding and control
Recorded hypertension prevalence is 10.3% (5,531 patients), below England (15.2%), Bolton (14.8%) and NHS Greater Manchester ICB (14.4%), though crude registers are unadjusted for age. Blood pressure control exceeds benchmarks, with 71.7% treated to target (England 70.3%) and 70.2% aged under 80 at <= 140/90 mmHg (England 67.8%). However, achievement for under-80s fell 3.3% over three years while England rose +3.2%, Bolton rose +1.0% and the ICB rose +3.6%. Slipping control for patients aged under 80 indicates an emerging gap in maintenance that systematic recall can address.
Lipids and statins
Patients with QRISK >= 20% receiving lipid-lowering therapy reach 72.7% (England 63.6%, Bolton 63.0%, ICB 67.0%), while diabetes primary prevention statin coverage sits at 78.8% (England 73.2%). High coverage is consistent with strong initiation; practices can focus on sustaining reviews.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 80,377 | £1.60 | £1.94 | £1.86 | £128,603 |
| Cardiovascular (all), 2025 | 105,903 | £2.81 | £3.15 | £3.33 | £297,587 |
For lipid-regulating drugs 2026, the PCN prescribed 80,377 items at £1.60 per item, below England (£1.86), Bolton (£1.81) and NHS Greater Manchester ICB (£1.94), spending £20,898 less than at England's unit cost across 80,377 items. Prescribing unit costs sit below comparators, representing lower expenditure per item rather than verified prescribing efficiency.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−1.00%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−2.41%
Asthma prevalence, PCN 3-yr % change
Recorded COPD prevalence is 1.2% (662 patients; England 1.9%) and asthma prevalence is 5.1% (2,493 patients; England 6.6%). Annual reviews reach 87.3% for COPD (England 76.4%) and 77.3% for asthma (England 65.7%), with youth second-hand smoke recording at 89.4% (England 78.8%). However, asthma review coverage fell 1.0% over three years (England +4.4%), leaving about 570 unreviewed patients. Youth asthma prescribing of 1,345 items per 1,000 (Bolton 2,033) is lower than borough rates; clinical audit would test diagnostic variation.
Cancer register and children's immunisation
Cancer QOF prevalence (all ages) is 1.4% at PCN level, below Bolton (LAD) (3.2%), NHS Greater Manchester Integrated Care Board (3.3%) and England (3.8%). Crude prevalence differences do not establish under-detection or unmet need; demographic factors and coding practices require local clinical verification.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Greater Manchester ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,270
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Greater Manchester ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 15% | 2,193 |
| Prostate | 61.7% | 53.2% | 14% | 1,788 |
| Breast | 82.5% | 85.4% | 19% | 1,758 |
| Bowel | 46.3% | 47.0% | 19% | 1,427 |
| Skin cancer | 84.5% | 87.8% | 27% | 580 |
In 2022, 55.6% of cancers with a known stage in NHS Greater Manchester ICB were diagnosed at stage 1 or 2 (6,491 of 11,679 staged cases; England 55.3%), standing 19.4 pp below the 75.0% national ambition. Known stage was recorded for 70.8% (11,679 of 16,492). Reaching 75.0% requires about 2,270 extra early diagnoses annually across the ICB. For the PCN, breast screening is 57.3% (Bolton 71.2%, England 69.9%) and cervical screening for ages 25–49 is 56.5% (England 66.8%), falling 3.0% over three years (England -1.0%). Crude cancer prevalence is 1.4% (England 3.8%). Screening uptake lags comparators, which clinical review can investigate.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
| Pathways within standard (%) | Bolton | Northern Care Alliance | Wrightington, Wigan and Leigh | Greater Manchester ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 80.48 | 75.20 | 82.80 | 79.53 | 79.32 |
| 31-day treatment (96%) | 96.50 | 94.54 | 89.04 | 96.49 | 92.50 |
| 62-day referral to treatment (85%) | 69.66 | 78.65 | 76.78 | 75.73 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Bolton | Northern Care Alliance | Wrightington, Wigan and Leigh | England |
|---|---|---|---|---|
| MRI | 2.05 | 5.09 | 0.49 | 21.40 |
| CT | 19.40 | 4.10 | 7.78 | 9.92 |
| Echocardiography | 3.48 | 31.48 | 24.37 | 28.48 |
| Colonoscopy | 1.33 | 40.04 | 6.10 | 30.83 |
| Gastroscopy | 2.06 | 36.48 | 12.54 | 29.02 |
| All 15 DM01 tests | 15.78 | 15.71 | 14.36 | 23.14 |
| Community services activity | Bolton residents | Greater Manchester ICB |
|---|---|---|
| Care contacts | 49,315 | 573,310 |
| Referrals | 4,075 | 94,470 |
| Patients with a contact | 17,765 | 183,535 |
Community services (residents of Bolton), Jun 2026 (provisional). In provisional Community Services Dataset records for June 2026, 51.6% of community contacts with Bolton borough residents were with adults aged 65 and over (25,460 of 49,315 contacts). Community provision heavily serves older residents, highlighting the need to coordinate neighbourhood care with secondary cancer and chronic disease services.
Practice variation and patient experience
Practice variation and patient experience
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Dr S Naseef | 95 | 100.0 | 87.7% | 81.9% | 93.0% |
| Bradford Street | 79 | 68.5 | 85.3% | 59.7% | 89.2% |
| Orient House | 83 | 83.7 | 80.1% | 81.7% | 85.9% |
| Bolton | 86 | 89.7 | 70.1% | 63.9% | 81.2% |
| Lever Chambers 2 | 87 | 89.6 | 64.6% | 76.8% | 81.1% |
| Deane | 81 | 100.0 | 64.0% | 73.7% | 78.5% |
| Bolton General | 63 | 100.0 | 62.1% | 68.7% | 78.2% |
| Olive | 68 | 97.3 | 75.1% | 85.3% | 75.7% |
| Great Lever One | 87 | 100.0 | 63.4% | 68.8% | 71.6% |
| Beehive Surgery | 77 | 76.7 | 52.6% | 78.3% | 69.3% |
| 3d Medical Centre | 42 | 100.0 | 81.5% | 90.6% | 65.8% |
| Al Fal Medical | 91 | 89.4 | 45.4% | 79.1% | 61.4% |
| Deane Clinic 1 | 130 | 77.6 | 62.5% | 65.6% | 61.1% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Twenty of 25 tracked measures trail England on three-year change despite high current achievement
Across 25 tracked indicators, 20 trail England's three-year change. Slower relative movement is led by heart failure functional reviews (+0.4% versus +8.7% in England, an 8.34-point shortfall), and hypertension treated to target, which fell 3.6% (England +3.6%, a 7.26-point shortfall). Both retain strong current achievement at 89.8% (England 78.5%) and 71.7% (England 70.3%). Relative three-year gains occurred in COPD reviews (+5.1% versus +2.8% in England) and smoking cessation support (+0.7 pp versus +0.1 pp), demonstrating that long-term slippage is not uniform across clinical domains.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
Hypertension treated to target
BP control, under 80
Alcohol record (psychosis)
QRISK statin treatment
COPD reviews
Smoking support (SMI)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Bolton (LAD) | Asset | PCN | Bolton (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 22 (702 beds) | n/a | Schools (catchment) | 73 | n/a |
| Children's centres | 6 | 18 | Places of worship | 53 | 144 |
| Libraries | 1 | 7 | Primary schools (LA maintained) | 17 | 61 |
| Primary academies | 9 | 32 | Special schools | 1 | 3 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Culturally adapted cancer screening recall
Breast screening coverage (aged 53 to 70) is 57.3% (England 69.9%, Bolton (LAD) 71.2%; difference vs England -12.6 percentage points) and cervical screening (aged 25 to 49, in the last 3.5 yrs) is 56.5% (England 66.8%; difference vs England -10.4 percentage points, with a 3-year change of -3.0% from 2023. Moderate effort to run.
Evidence base: uptake is the delivery measure of the national cancer screening programme; distance to the acceptable and achievable standards is the outreach target.
Policy anchor: Shift 3: sickness to prevention; Eliminate cervical cancer by 2040.
Option 2
Pre-school booster and MMR2 recall
In Q1 2025/26 (cohort 230), age-5 4-in-1 coverage is 81.5% (13.5 pp below 95.0%; England 80.9%), while MMR2 is 87.6% (9.4 pp below MMR1 at 97.0%). For discussion: practices could run targeted recall for children with MMR1 but no recorded MMR2 or 4-in-1 booster, offering flexible clinic slots. Low cost, quick to run.
Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.
Policy anchor: 10 Year Health Plan, shift from sickness to prevention.
Option 3
Structured annual asthma review recall
Asthma review coverage is 77.3% (above England's 65.7%) on a 2,493-patient register, leaving a scale indicator of about 570 unreviewed patients, while three-year coverage fell 1.0% (England +4.4%). For discussion: practices could standardise annual asthma review templates and offer after-school or holiday slots alongside inhaler prescribing checks. Low cost, quick to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Culturally adapted outreach review (p2) | Asian / Asian British | Neighbourhood health framework · Core20PLUS5 approach | PCN |
| Core20 list and volume reconciliation (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI health check review (p4) | Record of BMI in the last 12 months for patients on the MH register (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Hypertension recall audit (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Targeted screening uptake recall (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Option 1 · Culturally adapted cancer screening recall (p12) | Breast screening coverage: aged 53 to 70 years old · Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) · Asian / Asian British | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Option 2 · Pre-school booster and MMR2 recall (p12) | MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5 · 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Option 3 · Structured annual asthma review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
